- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
Amgen Canada Launches Adalimumab Biosimilar
Amgevita is now broadly available across Canada.
Amgen Canada has launched its adalimumab biosimilar (Amgevita), referencing Humira. The biosimilar is available for all indications of the reference product. These include rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn disease, and ulcerative colitis.
"We are pleased that Amgevita is now available in Canada, offering patients and physicians a treatment option and flexibility of choice in therapies they may not otherwise have," said Suna Avcil, executive medical director, Amgen Canada.
The company said Amgevita is now covered by public drug plans in the provinces of British Columbia, Alberta, Ontario, Quebec, New Brunswick, and Newfoundland. The biosimilar is available in prefilled syringe and prefilled pen forms.
Recently, Alberta expanded its biosimilar switching program to include adalimumab versions. Starting May 1, roughly 3300 patients currently prescribed Humira will switch to 1 of 5 adalimumab biosimilars. According to Biosimilars Canada, a trade group, adalimumab is one of the top selling biologics in Canada, where adalimumab biosimilars entered the market in February 2021. Alberta, British Columbia, and New Brunswick each have instituted switching policies to get patients started on lower cost biosimilar forms of adalimumab.
For more about Canada's biosimilar switching policies, click here.
How State Substitution Laws Shape Insulin Biosimilar Adoption
April 15th 2025States with fewer restrictions on biosimilar substitution tend to see higher uptake of interchangeable insulin glargine, showing how even small policy details can significantly influence biosimilar adoption and expand access to more affordable insulin.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
Experts Pressure Congress to Remove Roadblocks for Biosimilars
April 12th 2025Lawmakers and expert witnesses emphasized the potential of biosimilars to lower health care costs by overcoming barriers like pharmacy benefit manager practices, limited awareness, and regulatory delays to improve access and competition in chronic disease management during a recent congressional hearing.
Biosimilars Gastroenterology Roundup for November 2024—Podcast Edition
December 1st 2024On this episode of Not So Different, we discuss market changes in the adalimumab space; calls for PBM transparency and biosimilar access reforms grew; new data for biosimilars in gastroenterology conditions; and all the takeaways from this year's Global Biosimilars Week.
BioRationality: Commemorating the 15th Anniversary of the BPCIA
April 8th 2025Affirming that analytical characterization is often sufficient for biosimilar approval, minimizing unnecessary clinical testing, and enhancing FDA-led education to counter stakeholder misconceptions are key recommendations put forth in this opinion piece by Sarfaraz K. Niazi, PhD.
Early Success of Adalimumab Biosimilars Featured at AMCP 2025
April 5th 2025High adherence rates, comparable clinical effectiveness, and cost savings have marked the early adoption of adalimumab biosimilars in the US, particularly in formulary-driven transitions, as shown in 2 retrospective studies presented at the Academy of Managed Care Pharmacy annual meeting (AMCP 2025).
